sNN 0031

Drug Profile

sNN 0031

Alternative Names: rh PDGF-BB; sNN-0031

Latest Information Update: 26 Feb 2016

Price : $50

At a glance

  • Originator NeuroNova AB
  • Developer Newron Pharmaceuticals
  • Class Antiparkinsonians; Nerve growth factors
  • Mechanism of Action Neuron stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Parkinson's disease

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 26 Jan 2016 Newron terminates a phase I trial in Parkinson's disease in Sweden (NCT01829867)
  • 28 Oct 2015 Discontinued - Phase-II for Parkinson's disease (Treatment-experienced) in Germany (Intracerebral)
  • 28 Oct 2015 Discontinued - Phase-II for Parkinson's disease (Treatment-experienced) in Sweden (Intracerebral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top